 (AEZS) Stock, Quote.Headers.trade-ideas

Biotech

News

Penny Stocks

Health Care

General

AEZS

Aeterna Zentaris Shelves Early-Stage Vaccine Programs, Including COVID-19

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

AMZN

APLD

APLS

BRPM

BTBT

BTMD

CNTG

COIN

Core Scientific, Inc. - Class A Common Stock

CORZ

CPNG

CYCC

CYTO

DMTK

EOSE

FFHL

FFIE

GRRR

HCTI

HITI

HNST

HTGM

HUSA

IMTX

LIDR

LQDA

MARA

MRAI

MRTN

MSTR

MTCH

MYNA

NCNA

NFLX

NOTV

NVTA

NYXH

PXLW

RARE

SBNY

SDIG

SIDU

SKYX

STRY

SWVL

TBLT

TENX

THMO

TRKA

TUEM

TYDE

VERV

VOXX

WULF

Gainers


	Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue forecast.


Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday

Intraday Update

APRE

NYMX

XELA

Gainers


	Applied Blockchain, Inc. (NASDAQ: APLD) jumped 50.1% to $1.5907 after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue forecast.


This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday&#39;s Mid-Day Session

<p>COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEZS#NASDAQ">AEZS</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AEZS#TSX">AEZS</a>) ("COSCIENS" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announces that the Company's name has been changed from "Aeterna Zentaris Inc." to "COSCIENS Biopharma Inc.", effective as of August 6, 2024 (the "Name Change").<br /><br />&nbsp;</p>
<p>In addition, the Company announces that, effective as of August 9, 2024, the Company's common shares (the "Common Shares") will begin trading on the Toronto Stock Exchange (the "TSX") and NASDAQ Capital Market (the "NASDAQ") under the trading symbol "CSCI" and will concurrently cease trading thereon under the former trading symbol "AEZS".</p>


TSX:AEZS

Aeterna Zentaris Inc. Announces Name Change To COSCIENS Biopharma Inc. To Begin Trading Under The Trading Symbol "CSCI" August 9, 2024

Aeterna Zentaris Completes Phase 3 DETECT-Trial For Macimorelin In Diagnosing Childhood Onset Growth Hormone Deficiency; Top-Line Data And Full Study Results Expected In Q3 2024

<p>AEterna Zentaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEZS#NASDAQ">AEZS</a>) reported quarterly losses of $(4.74) per share which missed the analyst consensus estimate of $(0.81) by 485.19 percent. This is a 35.04 percent decrease over losses of $(3.51) per share from the same period last year.</p>


Earnings

AEterna Zentaris Q1 2024 GAAP EPS $(4.74) Vs. $(3.51) Last Year

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Aeterna Zentaris Announced That It Has Filed Articles Of Amendment To Effect The Previously Announced Share Consolidation (or Reverse Stock Split) Of Its Issued And Outstanding Common Shares

<p><strong>AEterna Zentaris</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEZS#NASDAQ">AEZS</a>) reported its Q4 earnings results on Wednesday, March 27, 2024 at 08:05 AM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>AEterna Zentaris missed estimated earnings by -20.0%, reporting an EPS of $-1.16 versus an estimate of $-0.97.</p>
<p>Revenue was down $2.36 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company missed on EPS by $0.24 which was followed by a 6.0% drop in the share price the next day.</p>
<p>Here's a look at AEterna Zentaris's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2023</strong></th>
<th><strong>Q2 2023</strong></th>
<th><strong>Q1 2023</strong></th>
<th><strong>Q4 2022</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.61</td>
<td>-0.87</td>
<td>-1.07</td>
<td>-0.93</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.85</td>
<td>-0.52</td>
<td>-0.88</td>
<td>-0.84</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.30M</td>
<td>1.14M</td>
<td>900K</td>
<td>1.06M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>3K</td>
<td>2.25M</td>
<td>2.13M</td>
<td>2.48M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for AEterna Zentaris <a href="https://www.benzinga.com/quote/AEZS/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AEterna Zentaris: Q4 Earnings Insights

<p>AEterna Zentaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEZS#NASDAQ">AEZS</a>) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(0.97) by 19.59 percent.  The company reported $100.000 thousand in sales this quarter. This is a 95.98 percent decrease over sales of $2.485 million the same period last year.</p>


Earnings Misses

AEterna Zentaris Q4 2023 GAAP EPS $(1.16) Misses $(0.97) Estimate, Sales $100.000K Down From $2.485M YoY

Aeterna Zentaris Completes Enrollment In Ongoing Pivotal DETECT-Trial For Diagnosis Of Childhood-Onset Growth Hormone Deficiency

Aeterna Zentaris, Ceapro Merger Approved by Securityholders At Special Meetings

CRPOF

Aeterna Zentaris Inks Pact With Ceapro To Create a Diversified Biopharmaceutical Company; Transaction Expected To Close In Q1 2024

Aeterna Zentaris Shares Were Halted Ahead Of News

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   maintains AEterna Zentaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEZS#NASDAQ">AEZS</a>) with a Buy and lowers the price target from $28 to $15.</p>


Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on AEterna Zentaris, Lowers Price Target to $15

<p>AEterna Zentaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEZS#NASDAQ">AEZS</a>) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.61) by 39.34 percent. This is a 21.43 percent decrease over losses of $(0.70) per share from the same period last year.</p>


AEterna Zentaris Q3 EPS $(0.85) Misses $(0.61) Estimate

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   reiterates AEterna Zentaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEZS#NASDAQ">AEZS</a>) with a Buy and maintains $28 price target.</p>


Reiteration

HC Wainwright & Co. Reiterates Buy on AEterna Zentaris, Maintains $28 Price Target

<p>AEterna Zentaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEZS#NASDAQ">AEZS</a>) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.87) by 40.23 percent. This is a 40.23 percent increase over losses of $(0.87) per share from the same period last year.  The company reported quarterly sales of $2.25 million which beat the analyst consensus estimate of $1.14 million by 97.02 percent.  This is a 1.11K percent increase over sales of $(222.00 thousand) the same period last year.</p>


AEterna Zentaris Q2 EPS $(0.52) Beats $(0.87) Estimate, Sales $2.25M Beat $1.14M Estimate

<div>The company reports strong financial position with cash&nbsp;projected&nbsp;to fund operations and advancement of priority pipeline programs into&nbsp;2025.</div>


Aeterna Zentaris Says Encouraged By Progress Across All Of Its Active Development Programs

<p>AEterna Zentaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEZS#NASDAQ">AEZS</a>) reported quarterly losses of $(0.88) per share which beat the analyst consensus estimate of $(1.07) by 17.76 percent. This is a 76 percent decrease over losses of $(0.50) per share from the same period last year.  The company reported quarterly sales of $2.10 million which beat the analyst consensus estimate of $900.00 thousand by 133.33 percent.  This is a 40.00 percent increase over sales of $1.50 million the same period last year.</p>


AEterna Zentaris Q1 EPS $(0.88) Beats $(1.07) Estimate, Sales $2.10M Beat $900.00K Estimate

Aeterna Zentaris Inc. (TSE:AEZS) has released an update. Aeterna Zentaris Inc. has received consent from an independent accounting firm for the inc...

Aeterna Zentaris Gains Key Accounting Consent

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>AEterna Zentaris</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/aezs-stock-quote/"><strong>AEZS</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>AEterna Zentaris reported earnings per share of -$4.74. This was below the analyst estimate for EPS of -81 cents.</li><li>The company reported revenue of $4,000.</li><li>This was 99.64% worse than the analyst estimate for revenue of $1.10 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/aezs-stock-earnings-aeterna-zentaris-for-q1-of-2024/">AEZS Stock Earnings: AEterna Zentaris Misses EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

AEZS Stock Earnings: AEterna Zentaris Misses EPS, Misses Revenue for Q1 2024

Aeterna Zentaris Inc. (TSE:AEZS) has released an update. Aeterna Zentaris Inc. reports a decrease in total assets from $37,016 thousand as of Decem...

Aeterna Zentaris Reports Q1 Financial Dip

Aeterna Zentaris Inc. (TSE:AEZS) has released an update. Aeterna Zentaris Inc. has completed a key share consolidation step ahead of its ‘merger of...

Aeterna Zentaris Finalizes Merger Details with Ceapro

Aeterna Zentaris (TSE:AEZS) has released an update. Aeterna Zentaris Inc., a biopharmaceutical firm, is requesting a court order to delay its annua...

Aeterna Zentaris Seeks Meeting Delay for Merger

Aeterna Zentaris (TSE:AEZS) has released an update. Aeterna Zentaris and Ceapro Inc. have successfully completed their merger, promising shareholde...

Aeterna Zentaris Merges With Ceapro, Eyeing Growth

Aeterna Zentaris (TSE:AEZS) has released an update. Aeterna Zentaris Inc. and Ceapro Inc. have officially completed their merger, creating a more d...

Aeterna Zentaris and Ceapro Announce Merger Completion

Aeterna Zentaris (TSE:AEZS) has released an update. Aeterna Zentaris has completed its Phase 3 DETECT-trial for macimorelin, a diagnostic test for ...

Aeterna Zentaris Wraps Up Key Pediatric Trial

Aeterna Zentaris (TSE:AEZS) has released an update. Aeterna Zentaris has issued a news release, however, it contains no text but rather a series of...

Aeterna Zentaris Release: A Technical Glitch?

Aeterna Zentaris (TSE:AEZS) has released an update. COSCIENS Biopharma Inc., formerly known as Aeterna Zentaris Inc., has officially changed its na...

COSCIENS Biopharma Debuts New Name and Ticker

Press Releases

Aeterna Zentaris Announces Effective Date of Share Consolidation

Aeterna Zentaris Reports First Quarter 2024 Financial Results

Aeterna Zentaris Announces Details Regarding Transaction with Ceapro

Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date

Aeterna Zentaris and Ceapro Complete Merger Transaction

Shareholder Alert: Ademi LLP investigates whether Aeterna Zentaris Inc.'s transaction with Ceapro was Fair to Shareholders

Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

(AEZS) Forecast

(AEZS) Stock, Quote.Headers.trade-ideas